Herantis Pharma considers listing to NASDAQ OMX First North Finland
Herantis Pharma Plc
Release 9 May 2014 at 10:00 a.m.
Not for release or distribution or publication in whole or in part in or into Australia, South-Africa, Hong Kong, Japan, Canada or The United States or any other jurisdiction in which the release, distribution or publication would be unlawful
Helsinki 9 May 2014 - Herantis Pharma Plc announced today in a seminar arranged by Helsinki stock exchange that it is considering the listing of its shares on First North Finland, a multilateral trading facility operated by NASDAQ OMX Helsinki Ltd. Herantis Pharma Plc also announced having been formed by the combining of two Finnish pharmaceutical companies, Hermo Pharma Ltd and Laurantis Pharma Ltd, on 29 April 2014.
Herantis Pharma Plc
Board of directors
Herantis Pharma Plc, Pekka Simula, Managing Director, mobile: +358 40 7300 445
Herantis Pharma Plc
Herantis Pharma Plc is a pharmaceutical company specialising in introducing early stage clinical research results for the purposes of clinical research aiming at developing new drugs. The company focuses on diseases for which treatment is not known or known treatments are insufficient. These diseases include for example dry eye syndrome, Parkinson's disease, and secondary lymphedema.
This press release is not a prospectus. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. Any such offer will be made solely on the basis of a prospectus to be published and registered with the Finnish Financial Supervisory Authority.
This document is not an offer for sale nor a solicitation of an offer to buy any securities in the United States or outside the European Economic Area . The securities may not be offered or sold in or into the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Herantis has not registered and will not register any part of its offering in the United States nor will it offer securities to the public in the United States.
This communication is only being distributed to and is directed only at (i) persons who are outside the United Kingdom, or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order, and (iv) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates will only be available to and will only be engaged in with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.
Securities in the company have not been, and will not be, registered under the applicable securities laws of Australia, Canada or Japan and may not be offered or sold within Australia, Canada or Japan or to, or for the account or benefit of, citizens or residents of Australia, Canada or Japan except under circumstances which will result in full compliance with the applicable laws and regulations promulgated by the relevant regulatory authorities in effect at the relevant time.
The company does not offer securities to the public in any Member State of the European Economic Area other than Finland. With respect to each Member State of the European Economic Area other than Finland (each, a "Relevant Member State"), no action has been undertaken to date to make an offer to the public of the securities requiring a publication of a prospectus in any Relevant Member State. As a result, the shares may only be offered in Relevant Member States in circumstances not requiring the company to publish a prospectus as provided under the Directive 2003/71/EC.
This company release contains forward looking statements. These forward looking statements include statements that are not historical facts and statements concerning inter alia Herantis' future revenues, financial position, financial standing, prospects, growth, strategies and its plans, beliefs and current expectations in relation to its field of business. By their very nature, forward looking statements involve inherent risks and uncertainties, since they relate to events or result from circumstances that may or may not occur in the future, and therefore they only describe the circumstances prevailing when the statement is given. Herantis cautions that forward looking statements or historical facts do not guarantee future performance and that its true revenues, financial position and financial standing and the development of the industry may significantly differ from the forward looking statements presented in this release. The company does not intend and does not assume any obligation to update any forward looking statement contained herein.